Pfizer to acquire migraine firm for over USD 11bn
![Photo: Dado Ruvic/REUTERS / X02714](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14005735.ece/ALTERNATES/schema-16_9/doc7kxkmblm0s0c48hta5l.jpg)
On Tuesday, Pfizer has announced its intention to acquire Biohaven Pharmaceuticals, agreeing to pay USD 148.5 per share in cash, which equals to a whopping price tag of USD 11.6bn, a company press release reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck's migraine drug approved in EU
For subscribers